董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Weingarten | 男 | Director,Chairman of the Board | 71 | 8.09万美元 | 未持股 | 2023-10-03 |
| Mark Goldstone | 男 | Director | 60 | 4.39万美元 | 未持股 | 2023-10-03 |
| Donald A. Gagliano | 男 | Director | 70 | 2.69万美元 | 未持股 | 2023-10-03 |
| Michaela Griggs | 女 | Director | 57 | 2.27万美元 | 未持股 | 2023-10-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Craig Sheehan | 男 | Chief Commercial Officer | 52 | 25.69万美元 | 未持股 | 2023-10-03 |
| Janet Hall | 女 | President and Chief Executive Officer | 64 | 未披露 | 未持股 | 2023-10-03 |
| Katie Cox | 女 | Chief Accounting Officer | 53 | 未披露 | 未持股 | 2023-10-03 |
董事简历
中英对照 | 中文 | 英文- Robert Weingarten
-
Robert Weingarten自2015年6月起担任公司董事，自2020年7月起担任董事会主席。此前，Weingarten先生于2017年1月至2020年3月担任我们董事会的首席董事。他是一位经验丰富的商业顾问和顾问，拥有持续的咨询实践。1979年以来，他曾提供财务咨询和顾问服务，并任职于几个上市公司的董事会，处于不同的发展、运营或重组阶段。2017年7月至2018年6月，Weingarten先生是Alltemp，Inc.的首席财务官。2013年4月至2017年2月，Weingarten先生担任RespireRx Pharmaceuticals Inc.的董事会成员。OTCQB:RSPI，也担任Vice President和首席财务官。Weingarten先生于1974年在华盛顿大学（University of Washington）获得会计学学士学位，并于1975年在南加州大学（University of Southern California）获得金融学工商管理硕士学位，是加利福尼亚州（California）的注册会计师（不活跃）。
Robert Weingarten,has been a Director since June 2015 and Chairman of the board of directors since July 2020. Since June 2020, Mr. Weingarten has served as the Company's non-employee corporate secretary. Previously, Mr. Weingarten served as Lead Director on Guardion Health Sciences, Inc. board of directors from January 2017 to March 2020. He is an experienced business consultant and advisor with an ongoing consulting practice focused on accounting and financial compliance for public companies. Since 1979, he has provided financial consulting and advisory services and served on boards of directors of several public companies in various stages of development, operation or reorganization. Since August 2020, Mr. Weingarten has been the Vice President and Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (NASDAQ-CM: LIXT). Mr. Weingarten received a B.A. in Accounting from the University of Washington in 1974, a M.B.A. in Finance from the University of Southern California in 1975, and is a Certified Public Accountant (inactive) in the State of California. Mr. Weingarten has considerable accounting and finance experience, particularly with regard to public company reporting requirements. - Robert Weingarten自2015年6月起担任公司董事，自2020年7月起担任董事会主席。此前，Weingarten先生于2017年1月至2020年3月担任我们董事会的首席董事。他是一位经验丰富的商业顾问和顾问，拥有持续的咨询实践。1979年以来，他曾提供财务咨询和顾问服务，并任职于几个上市公司的董事会，处于不同的发展、运营或重组阶段。2017年7月至2018年6月，Weingarten先生是Alltemp，Inc.的首席财务官。2013年4月至2017年2月，Weingarten先生担任RespireRx Pharmaceuticals Inc.的董事会成员。OTCQB:RSPI，也担任Vice President和首席财务官。Weingarten先生于1974年在华盛顿大学（University of Washington）获得会计学学士学位，并于1975年在南加州大学（University of Southern California）获得金融学工商管理硕士学位，是加利福尼亚州（California）的注册会计师（不活跃）。
- Robert Weingarten,has been a Director since June 2015 and Chairman of the board of directors since July 2020. Since June 2020, Mr. Weingarten has served as the Company's non-employee corporate secretary. Previously, Mr. Weingarten served as Lead Director on Guardion Health Sciences, Inc. board of directors from January 2017 to March 2020. He is an experienced business consultant and advisor with an ongoing consulting practice focused on accounting and financial compliance for public companies. Since 1979, he has provided financial consulting and advisory services and served on boards of directors of several public companies in various stages of development, operation or reorganization. Since August 2020, Mr. Weingarten has been the Vice President and Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (NASDAQ-CM: LIXT). Mr. Weingarten received a B.A. in Accounting from the University of Washington in 1974, a M.B.A. in Finance from the University of Southern California in 1975, and is a Certified Public Accountant (inactive) in the State of California. Mr. Weingarten has considerable accounting and finance experience, particularly with regard to public company reporting requirements.
- Mark Goldstone
-
Mark Goldstone自2015年6月起担任董事。Goldstone先生在梦百合行业拥有超过25年的经验，包括运营、商业化和咨询。他已经为技术、生命科学和梦百合服务行业的一系列中间市场和新兴成长型公司完成了许多合并、收购、融资和战略伙伴关系交易，这使他有资格担任董事会成员。Goldstone从2007年到2013年担任DDB Worldwide Communications Group Inc.梦百合业务全球总裁，负责覆盖超过36个市场40多个办事处的全球通信业务。业务涵盖广告、数字、综合传播、梦百合专业推广、品牌、命名、设计、市场塑造、医学教育和科学传播。Goldstone先生此前曾在Publicis梦百合Communications Group担任高级职位，负责全球赛诺菲-安万特业务，并在Interbrand担任其全球梦百合业务首席执行官。他曾任职Havas Group（从英国搬到纽约），在那里他曾担任Robert A.Becker公司、Euro RSCG公司、Jordan McGrath Case&Partners公司、Euro RSCG公司（最终任职Euro RSCG Worldwide总部）的高级职务（从1996年到2003年）。在那里，他帮助设计和建立了他们的全球梦百合业务——Euro RSCG Life Worldwide现在有了自己的生活。Goldstone先生拥有药学学士学位（荣誉）。他是享有盛誉的Galian Foundation的董事会成员，以及G3Global Genomics Group的董事会成员。他是英国皇家制药学会（Royal Pharmaceutical Society of Great Britain）的成员，也是美国糖尿病协会（the American Diabetes Association）的纽约企业发展的前任联席主席。Goldstone先生在梦百合行业的销售、营销和战略交易方面的丰富经验对公司发展业务、将产品商业化和建立营销渠道特别有用。
Mark Goldstone,has been a Director since June 2015. Mr. Goldstone has over 25 years of experience in the healthcare industry, encompassing operations, commercialization, consulting, mergers and acquisitions and venture capital. He has led some of the largest specialist consulting and communications groups in the world and was a founding partner at Forepont Capital (VC). Previously, he was COO of EuroRSCG Life (now Havas), Global CEO of healthcare at top brand and business consultancy, Interbrand and Worldwide President of Doyle, Dane and Bernbach global healthcare businesses. He has developed successful commercialization strategies and programs from early-stage and market development, to product launch and late-stage lifecycle management for blue-chip pharmaceutical and packaged goods companies including Pfizer, Merck, Novartis, Bayer, GSK, Sanofi, Colgate Palmolive, L'Oreal, Danone, Johnson & Johnson, Roche. Mr Goldstone began his career as a clinical Pharmacist and is a member of the Royal Pharmaceutical Society. He is board member of the prestigious Galien Foundation and the Industry Advisory Board for the UK Government's BRCD initiative. Mr. Goldstone's breadth of experience in sales, marketing and strategic transactions in the healthcare industry is particularly Guardion Health Sciences, Inc. eful to the Company as it develops its business, commercializes it products and builds its marketing channels. - Mark Goldstone自2015年6月起担任董事。Goldstone先生在梦百合行业拥有超过25年的经验，包括运营、商业化和咨询。他已经为技术、生命科学和梦百合服务行业的一系列中间市场和新兴成长型公司完成了许多合并、收购、融资和战略伙伴关系交易，这使他有资格担任董事会成员。Goldstone从2007年到2013年担任DDB Worldwide Communications Group Inc.梦百合业务全球总裁，负责覆盖超过36个市场40多个办事处的全球通信业务。业务涵盖广告、数字、综合传播、梦百合专业推广、品牌、命名、设计、市场塑造、医学教育和科学传播。Goldstone先生此前曾在Publicis梦百合Communications Group担任高级职位，负责全球赛诺菲-安万特业务，并在Interbrand担任其全球梦百合业务首席执行官。他曾任职Havas Group（从英国搬到纽约），在那里他曾担任Robert A.Becker公司、Euro RSCG公司、Jordan McGrath Case&Partners公司、Euro RSCG公司（最终任职Euro RSCG Worldwide总部）的高级职务（从1996年到2003年）。在那里，他帮助设计和建立了他们的全球梦百合业务——Euro RSCG Life Worldwide现在有了自己的生活。Goldstone先生拥有药学学士学位（荣誉）。他是享有盛誉的Galian Foundation的董事会成员，以及G3Global Genomics Group的董事会成员。他是英国皇家制药学会（Royal Pharmaceutical Society of Great Britain）的成员，也是美国糖尿病协会（the American Diabetes Association）的纽约企业发展的前任联席主席。Goldstone先生在梦百合行业的销售、营销和战略交易方面的丰富经验对公司发展业务、将产品商业化和建立营销渠道特别有用。
- Mark Goldstone,has been a Director since June 2015. Mr. Goldstone has over 25 years of experience in the healthcare industry, encompassing operations, commercialization, consulting, mergers and acquisitions and venture capital. He has led some of the largest specialist consulting and communications groups in the world and was a founding partner at Forepont Capital (VC). Previously, he was COO of EuroRSCG Life (now Havas), Global CEO of healthcare at top brand and business consultancy, Interbrand and Worldwide President of Doyle, Dane and Bernbach global healthcare businesses. He has developed successful commercialization strategies and programs from early-stage and market development, to product launch and late-stage lifecycle management for blue-chip pharmaceutical and packaged goods companies including Pfizer, Merck, Novartis, Bayer, GSK, Sanofi, Colgate Palmolive, L'Oreal, Danone, Johnson & Johnson, Roche. Mr Goldstone began his career as a clinical Pharmacist and is a member of the Royal Pharmaceutical Society. He is board member of the prestigious Galien Foundation and the Industry Advisory Board for the UK Government's BRCD initiative. Mr. Goldstone's breadth of experience in sales, marketing and strategic transactions in the healthcare industry is particularly Guardion Health Sciences, Inc. eful to the Company as it develops its business, commercializes it products and builds its marketing channels.
- Donald A. Gagliano
-
DonaldA.Gagliano自公司于2019年4月9日首次公开募股以来一直担任董事。此外，Gagliano博士自2015年6月起担任我们的科学顾问委员会成员。自2018年10月以来，Gagliano博士一直担任GMIC LLC的负责人，该公司主要为健康系统工程和眼科主题专家提供梦百合咨询服务。Gagliano博士目前没有担任任何董事职务，在过去五年内也没有担任任何董事职务。从2013年4月到2013年10月，Gagliano博士担任Bausch+Lomb，Inc.的全球医疗事务Vice President。2016年至今，Gagliano博士担任预防失明协会（Prevention of Blinness Society）的总裁。从2008年11月到2013年3月，Gagliano博士担任国防部负责卫生事务的助理部长，担任国防部国防部和退伍军人事务部（VA）愿景卓越中心（VCE）的第一任执行董事。1975年，Gagliano博士毕业于美国西点军校（US Military Academy at Westpoint），获得工程学学位。1981年，他在芝加哥医学院获得医学学士学位，1998年，他在宾夕法尼亚州立大学获得梦百合管理硕士学位。
Donald A. Gagliano,has served as a Director since the Company's initial public offering on April 9, 2019. Additionally, Dr. Gagliano has been a member of Guardion Health Sciences, Inc. Scientific Advisory Board since June 2015. Since October 2018, Dr. Gagliano has been the principal of GMIC LLC, which provides healthcare consultation services primarily for health systems engineering and ophthalmology subject matter expertise. Dr. Gagliano does not currently hold any directorships and has not held any directorships within the past five years. From April 2013 to October 2013, Dr. Gagliano was the Vice President for Global Medical Affairs for Bausch+Lomb, Inc. From 2016 to present, Dr. Gagliano has served as the President and Immediate Past President of the Prevention of Blindness Society. From November 2008 to March 2013, Dr. Gagliano served under the Assistant Secretary of Defense for Health Affairs as the first Executive Director of the Joint Department of Defense and Department of Veterans Affairs Vision Center of Excellence. In 1975, Dr. Gagliano graduated from the US Military Academy at WestPoint with a degree in Engineering. In 1981, he received a Bachelor of Science in medicine from Chicago Medical School and in 1998 he received his Master of Healthcare Administration from Penn State University. Dr. Gagliano's breadth of experience in the healthcare industry is particularly Guardion Health Sciences, Inc. eful to the Company as it develops its business, commercializes products and builds its marketing channels. - DonaldA.Gagliano自公司于2019年4月9日首次公开募股以来一直担任董事。此外，Gagliano博士自2015年6月起担任我们的科学顾问委员会成员。自2018年10月以来，Gagliano博士一直担任GMIC LLC的负责人，该公司主要为健康系统工程和眼科主题专家提供梦百合咨询服务。Gagliano博士目前没有担任任何董事职务，在过去五年内也没有担任任何董事职务。从2013年4月到2013年10月，Gagliano博士担任Bausch+Lomb，Inc.的全球医疗事务Vice President。2016年至今，Gagliano博士担任预防失明协会（Prevention of Blinness Society）的总裁。从2008年11月到2013年3月，Gagliano博士担任国防部负责卫生事务的助理部长，担任国防部国防部和退伍军人事务部（VA）愿景卓越中心（VCE）的第一任执行董事。1975年，Gagliano博士毕业于美国西点军校（US Military Academy at Westpoint），获得工程学学位。1981年，他在芝加哥医学院获得医学学士学位，1998年，他在宾夕法尼亚州立大学获得梦百合管理硕士学位。
- Donald A. Gagliano,has served as a Director since the Company's initial public offering on April 9, 2019. Additionally, Dr. Gagliano has been a member of Guardion Health Sciences, Inc. Scientific Advisory Board since June 2015. Since October 2018, Dr. Gagliano has been the principal of GMIC LLC, which provides healthcare consultation services primarily for health systems engineering and ophthalmology subject matter expertise. Dr. Gagliano does not currently hold any directorships and has not held any directorships within the past five years. From April 2013 to October 2013, Dr. Gagliano was the Vice President for Global Medical Affairs for Bausch+Lomb, Inc. From 2016 to present, Dr. Gagliano has served as the President and Immediate Past President of the Prevention of Blindness Society. From November 2008 to March 2013, Dr. Gagliano served under the Assistant Secretary of Defense for Health Affairs as the first Executive Director of the Joint Department of Defense and Department of Veterans Affairs Vision Center of Excellence. In 1975, Dr. Gagliano graduated from the US Military Academy at WestPoint with a degree in Engineering. In 1981, he received a Bachelor of Science in medicine from Chicago Medical School and in 1998 he received his Master of Healthcare Administration from Penn State University. Dr. Gagliano's breadth of experience in the healthcare industry is particularly Guardion Health Sciences, Inc. eful to the Company as it develops its business, commercializes products and builds its marketing channels.
- Michaela Griggs
-
Michaela Griggs自2021年12月9日起担任董事。自2023年1月起，Griggs女士担任Forefront Dermatology的首席医学美学官和首席化妆品官。从2020年10月到2020年12月，格里格斯女士一直担任总部位于洛杉矶的南加州生殖中心的首席执行官，该中心是一家领先的多地点生育和生殖中心运营商。从2017年1月至2020年10月，Griggs女士担任服装公司Barco Uniforms的健康护理和身份部门的执行副总裁，从2015年8月至2016年11月，她担任Tria Beauty的总经理、NA和全球营销副总裁（首席营销官）。此外，Griggs女士还在艾尔建、拜耳医疗和3M Unitek担任重要的市场营销主管职位，在此期间，她帮助开发和改进了Botox 、Juvederm 、One-A-Day 复合维生素等全球品牌的品牌、零售和分销战略，以及其他重要的品牌组合。Griggs女士获得了伦敦商业和金融学院/威尔士大学的工商管理硕士学位，并获得了谢菲尔德/利兹光学学院的英国正畸学会（DBO）文凭。
Michaela Griggs,has been a director since December 9, 2021. Since January 2023, Mrs. Griggs has served as Chief Medical Aesthetics Officer and Chief Cosmetics Officer of Forefront Dermatology. From October 2020 through December 2020, Mrs. Griggs has served as the Chief Executive Officer of Los Angeles-based Southern California Reproductive Center, a leading operator of multi-location fertility and reproductive centers. From January 2017 until October 2020, Mrs. Griggs served as Executive Vice President of Barco Uniforms' Health Care & Identity Divisions, an apparel company, and from August 2015 until November 2016, she served as General Manager, NA & VP Global Marketing (Chief Marketing Officer) of Tria Beauty. In addition, Mrs. Griggs held key executive marketing positions at Allergan, Bayer Healthcare and 3M Unitek, where she was instrumental in developing and improving brand, retail and distribution strategies for global brands such as Botox, Juvederm, and One-A-Day multi-vitamins, as well as other key brand portfolios. Mrs. Griggs earned a Master's in Business Administration degree from the London School of Business and Finance/University of Wales, and her Diploma of the British Orthoptic Society (DBO) from Sheffield/Leeds School of Orthoptics. - Michaela Griggs自2021年12月9日起担任董事。自2023年1月起，Griggs女士担任Forefront Dermatology的首席医学美学官和首席化妆品官。从2020年10月到2020年12月，格里格斯女士一直担任总部位于洛杉矶的南加州生殖中心的首席执行官，该中心是一家领先的多地点生育和生殖中心运营商。从2017年1月至2020年10月，Griggs女士担任服装公司Barco Uniforms的健康护理和身份部门的执行副总裁，从2015年8月至2016年11月，她担任Tria Beauty的总经理、NA和全球营销副总裁（首席营销官）。此外，Griggs女士还在艾尔建、拜耳医疗和3M Unitek担任重要的市场营销主管职位，在此期间，她帮助开发和改进了Botox 、Juvederm 、One-A-Day 复合维生素等全球品牌的品牌、零售和分销战略，以及其他重要的品牌组合。Griggs女士获得了伦敦商业和金融学院/威尔士大学的工商管理硕士学位，并获得了谢菲尔德/利兹光学学院的英国正畸学会（DBO）文凭。
- Michaela Griggs,has been a director since December 9, 2021. Since January 2023, Mrs. Griggs has served as Chief Medical Aesthetics Officer and Chief Cosmetics Officer of Forefront Dermatology. From October 2020 through December 2020, Mrs. Griggs has served as the Chief Executive Officer of Los Angeles-based Southern California Reproductive Center, a leading operator of multi-location fertility and reproductive centers. From January 2017 until October 2020, Mrs. Griggs served as Executive Vice President of Barco Uniforms' Health Care & Identity Divisions, an apparel company, and from August 2015 until November 2016, she served as General Manager, NA & VP Global Marketing (Chief Marketing Officer) of Tria Beauty. In addition, Mrs. Griggs held key executive marketing positions at Allergan, Bayer Healthcare and 3M Unitek, where she was instrumental in developing and improving brand, retail and distribution strategies for global brands such as Botox, Juvederm, and One-A-Day multi-vitamins, as well as other key brand portfolios. Mrs. Griggs earned a Master's in Business Administration degree from the London School of Business and Finance/University of Wales, and her Diploma of the British Orthoptic Society (DBO) from Sheffield/Leeds School of Orthoptics.
高管简历
中英对照 | 中文 | 英文- Craig Sheehan
Craig Sheehan自2021年6月起担任我们的首席商务官。在此之前的四年中，Sheehan先生是Viactiv品牌产品的高级主管，之前的所有者是Adare Pharmaceuticals，Inc.。在加入Adare Pharmaceuticals，Inc.之前，Sheehan先生在Church&Dwight担任了20年的关键营销领导职务，在那里他推动了Arm&Hammer、First Response、Oxiclean和VitaFusion等标志性的、有科学依据的品牌的增长。
Craig Sheehan,has served as Guardion Health Sciences, Inc. Chief Commercial Officer since June 2021 when Guardion Health Sciences, Inc. acquired the Vicativ brand. For the prior four years, Mr. Sheehan was the senior executive responsible for the Viactiv brand of products with the prior owner, Adare Pharmaceuticals, Inc. Prior to Adare Pharmaceuticals, Inc., Mr. Sheehan spent 20 years in key marketing leadership positions at Church & Dwight, where he drove the growth of such iconic, science-backed brands as Arm & Hammer, First Response, OxiClean, and Vitafusion.- Craig Sheehan自2021年6月起担任我们的首席商务官。在此之前的四年中，Sheehan先生是Viactiv品牌产品的高级主管，之前的所有者是Adare Pharmaceuticals，Inc.。在加入Adare Pharmaceuticals，Inc.之前，Sheehan先生在Church&Dwight担任了20年的关键营销领导职务，在那里他推动了Arm&Hammer、First Response、Oxiclean和VitaFusion等标志性的、有科学依据的品牌的增长。
- Craig Sheehan,has served as Guardion Health Sciences, Inc. Chief Commercial Officer since June 2021 when Guardion Health Sciences, Inc. acquired the Vicativ brand. For the prior four years, Mr. Sheehan was the senior executive responsible for the Viactiv brand of products with the prior owner, Adare Pharmaceuticals, Inc. Prior to Adare Pharmaceuticals, Inc., Mr. Sheehan spent 20 years in key marketing leadership positions at Church & Dwight, where he drove the growth of such iconic, science-backed brands as Arm & Hammer, First Response, OxiClean, and Vitafusion.
- Janet Hall
Janet Hall，自2023年6月19日起担任Guardion Health Sciences, Inc.总裁兼首席执行官。霍尔女士在大型消费者健康和消耗品领域是一位备受尊敬的资深人士，她拥有丰富的商业经验和成就，包括在蓝筹公司担任高级管理职位，如曾担任露得清公司北美总裁的强生，以及曾担任消费者营销高级副总裁兼总经理的The Coca-Cola Company。霍尔的营销生涯始于联合饼干和吉百利史威士，后来进入消费者健康领域，在葛兰素史克旗下的SmithKline Beecham担任高级营销职务。最近，霍尔女士是M2 Ingredients的首席执行官，这是一家垂直整合的公司，拥有FDA注册的受控环境设施，用于种植、加工和包装功能性食品和营养产品。
Janet Hall,has served as Guardion Health Sciences, Inc. President and Chief Executive Office since June 19, 2023. Ms. Hall is a highly regarded veteran of big consumer health and consumables and accomplishments, including senior executive positions with blue-chip companies such as Johnson & Johnson, where she was President, North America of te Neutrogena Company, and The Coca-Cola Company, where she was SVP & General manager of Consumer Marketing. Ms. Hall started her marketing career at United Biscuits and Cadbury Schweppes, and moved into the consumer health sector with senior marketing roles at SmithKline Beecham (GlaxoSmithKline). Most recently, Ms. Hall was Chief Executive Officer of M2 Ingredients, a vertically integrated company with an FDA registered controlled environment facility that grows, processes and packages functional foods and nutritional products.- Janet Hall，自2023年6月19日起担任Guardion Health Sciences, Inc.总裁兼首席执行官。霍尔女士在大型消费者健康和消耗品领域是一位备受尊敬的资深人士，她拥有丰富的商业经验和成就，包括在蓝筹公司担任高级管理职位，如曾担任露得清公司北美总裁的强生，以及曾担任消费者营销高级副总裁兼总经理的The Coca-Cola Company。霍尔的营销生涯始于联合饼干和吉百利史威士，后来进入消费者健康领域，在葛兰素史克旗下的SmithKline Beecham担任高级营销职务。最近，霍尔女士是M2 Ingredients的首席执行官，这是一家垂直整合的公司，拥有FDA注册的受控环境设施，用于种植、加工和包装功能性食品和营养产品。
- Janet Hall,has served as Guardion Health Sciences, Inc. President and Chief Executive Office since June 19, 2023. Ms. Hall is a highly regarded veteran of big consumer health and consumables and accomplishments, including senior executive positions with blue-chip companies such as Johnson & Johnson, where she was President, North America of te Neutrogena Company, and The Coca-Cola Company, where she was SVP & General manager of Consumer Marketing. Ms. Hall started her marketing career at United Biscuits and Cadbury Schweppes, and moved into the consumer health sector with senior marketing roles at SmithKline Beecham (GlaxoSmithKline). Most recently, Ms. Hall was Chief Executive Officer of M2 Ingredients, a vertically integrated company with an FDA registered controlled environment facility that grows, processes and packages functional foods and nutritional products.
- Katie Cox
Katie Cox自2023年7月25日起担任Guardion Health Sciences, Inc.首席会计官，在此之前，Cox女士自2022年6月起担任公司财务规划和分析主管。在加入公司之前，Cox女士于2019年9月至2022年6月担任Catalent, Inc.（纽约证券交易所代码：CTLT）子公司Catalent制药解决方案的财务规划和分析总监。2009年9月至2019年9月，Cox女士担任百特国际（纽约证券交易所代码：BAX）子公司Baxter Pharmaceutical Solutions，LLC的财务经理。考克斯拥有印第安纳大学心理学学士学位和印第安纳卫斯理大学MBA学位。
Katie Cox,has served as Guardion Health Sciences, Inc. Chief Accounting Officer since July 25, 2023 and prior thereto from June 2022, Ms. Cox served as the Company's Head of Financial Planning and Analysis. Prior to joining the Company, Ms. Cox served as Director of Financial Planning and Analysis of Catalent Pharma Solutions, a subsidiary of Catalent, Inc. (NYSE: CTLT) from September 2019 through June 2022. From September 2009 through September 2019, Ms. Cox served as Finance Manager of Baxter Pharmaceutical Solutions, LLC, a subsidiary of Baxter International (NYSE: BAX). Ms. Cox holds a BA in Psychology from Indiana University and an MBA from Indiana Wesleyan University.- Katie Cox自2023年7月25日起担任Guardion Health Sciences, Inc.首席会计官，在此之前，Cox女士自2022年6月起担任公司财务规划和分析主管。在加入公司之前，Cox女士于2019年9月至2022年6月担任Catalent, Inc.（纽约证券交易所代码：CTLT）子公司Catalent制药解决方案的财务规划和分析总监。2009年9月至2019年9月，Cox女士担任百特国际（纽约证券交易所代码：BAX）子公司Baxter Pharmaceutical Solutions，LLC的财务经理。考克斯拥有印第安纳大学心理学学士学位和印第安纳卫斯理大学MBA学位。
- Katie Cox,has served as Guardion Health Sciences, Inc. Chief Accounting Officer since July 25, 2023 and prior thereto from June 2022, Ms. Cox served as the Company's Head of Financial Planning and Analysis. Prior to joining the Company, Ms. Cox served as Director of Financial Planning and Analysis of Catalent Pharma Solutions, a subsidiary of Catalent, Inc. (NYSE: CTLT) from September 2019 through June 2022. From September 2009 through September 2019, Ms. Cox served as Finance Manager of Baxter Pharmaceutical Solutions, LLC, a subsidiary of Baxter International (NYSE: BAX). Ms. Cox holds a BA in Psychology from Indiana University and an MBA from Indiana Wesleyan University.